Table 1 Baseline characteristics of included studies
Author (year) | patient source(country) | Study design | Study period | Treatment | Sample size | Age | ctDNA state | Outcome | Follow-up (months) | NOS SCORE |
|---|---|---|---|---|---|---|---|---|---|---|
Carrasco et al. 2023 [35] | Spain | PCS | 2019–2022 | NAC + RC/RC + AC | 42 | 67(50–80) | Positive/Negative | PFS | 21(6–37) | 8 |
Lindskrog et al.2023 [36] | Denmark | RCS | 2001–2016 | RC | 102 | 69{62–75} | Positive/Negative | RFS/OS | 72 | 8 |
Papadimitriou et al.2023 [37] | Athens | PCS | NA | RC | 86 | 70 | High/Low** | OS/MFS | 41[36.2–45.8] | 7 |
van Dorp et al. 2023 [39] | Multi-country | PCS | 2017.12-2021.1 | NAC + RC | 41 | 70{65–73} | Positive/Negative | PFS | 11.7 | 8 |
Patel et al. 2017 [33] | Netherlands | PCS | 2014.3-2015.10 | NAC + RC/CR/RAD | 17 | 59 | Positive/Negative | RFS | 24.7(16–32) | 9 |
Lindskrog* et al. 2023 [36] | Denmark | PCS | 2013–2017 | NAC + RC | 68 | 67{59–71} | Positive/Negative Clearance/Remnant | RFS/OS | 68 | 8 |
Szabados et al. 2022 [38] | Multi-country | PCS | 2016.5-2020.6 | NAC + RC | 95 | 73(53–87) | Positive/Negative | RFS | 25[25–26] | 8 |
Vandekerkhove et al. 2021 [34] | Canada | RCS | 2014.12-2018.11 | NAC + RC | 39 | 67(37–88) | Positive/Negative | OS/RFS | 8.4 (0.3–33) | 7 |
Powles et al. 2021 [40] | Multi-country | RCS | 2015.10-2019.11 | NAC + RC + AC/RC + AC/AC | 581 | 67(31–88) | Positive/Negative | DFS/OS | 21.9(16–45) | 9 |
Powles et al. 2023 [43] | Multi-country | RCS | 2015.10-2021.11 | NAC + RC + AC/RC + AC/AC | 581 | 67(31–88) | Positive/Negative | DFS/OS | 46.8{36.1–53.6} | 9 |
Christensen et al. 2022 [42] | Denmark | PCS | 2013–2019 | NAC + RC | 92 | NR | Clearance/Remnant | RFS | 41.3 | 7 |
Carrasco et al. 2022 [41] | Spain | PCS | 2018–2021 | NAC + RC/RC + AC | 37 | 71(51–85) | Positive/Negative | PFS | 36 | 8 |